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Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USASummary Vitamin D metabolismVitamin D is increasingly becoming recognized as an important
physiological regulator with pleiotropic functions outside of its
classical role in skeletal homeostasis. A growing body of clinical
evidence highlights the prevalence and risks of vitamin D deﬁ-
ciency in patients suffering from chronic hepatitis C infection,
and vitamin D supplementation has been proposed as an adjunct
to current standards of care. This review considers the experi-
mental evidence for the anti-inﬂammatory, antiﬁbrotic and anti-
viral effects of vitamin D, and discusses the therapeutic potential
of vitamin D supplementation to protect against liver disease
progression and improve responses to treatment.
 2012 European Association for the Study of the Liver. Published
by Elsevier Inc. All rights reserved.Introduction
Advances in hepatitis C virus (HCV) pharmaceutical development
are being made at a blistering pace; however, highly effective,
non-toxic therapies remain a hope for the future. This leaves an
immediate need for interventions that can minimize disease pro-
gression and/or improve sustained virological response (SVR) rates
in the short term. The aging of the HCV-positive population is cre-
ating an epidemic of end stage liver disease. Many patients cannot
wait for second and third generation direct acting antiviral drugs to
reach the clinic. As an interimmeasure, vitaminD supplements have
been proposed as an adjunct to pegylated-interferon and ribavirin.
This review integrates the known biological effects of the vitamin D
system with recent clinical ﬁndings and discusses the therapeutic
potential of vitamin D supplementation in HCV-positive patients.Journal of Hepatology 20
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factor receptor.Unlike most vitamins, vitamin D is neither an enzyme co-factor
nor an essential nutrient that must be obtained from food. Rather,
it is a precursor of a seco-steroid hormone. Vitamin D can be
manufactured endogenously from 7-dehydrocholesterol when
skin is exposed to ultraviolet B radiation (Fig. 1). Historically,
sun exposure was the main source of vitamin D, but food and
supplements are now important sources, especially among urban
populations and people who work indoors. During its conversion
from a precursor to an active hormone, vitamin D is ﬁrst modiﬁed
in the liver by microsomal vitamin D 25-hydroxylases, which
form 25-hydroxyvitamin D [25(OH)D], a stable metabolite that
is the best single indicator of vitamin D status [1]. A second
hydroxylation step, mediated by the mitochondrial cytochrome
P450 oxidase, CYP27B1, produces the most biologically active
metabolite, 1,25-dihydroxyvitamin D [1,25(OH)2D]. In individu-
als with adequate renal function, most of the circulating
1,25(OH)2D is produced by the kidney; however, CYP27B1 activ-
ity occurs in many extra-renal tissues, including innate immune
cells, such as macrophages and dendritic cells. The local metabo-
lism of 25(OH)D by these cells is likely to be an important factor
in generating the high local concentrations of 1,25(OH)2D needed
for its paracrine and autocrine activities.
1,25(OH)2D mediates most of its biological effects by binding
to the vitamin D receptor (VDR), which is expressed at some level
in almost all human tissues. In the absence of its ligand, the VDR
largely exists as an inactive homodimer. Upon binding
1,25(OH)2D, the VDR is phosphorylated and forms a heterodimer
with its preferred binding partner, the retinoid X receptor (RXR),
forming a nuclear transcription factor. This VDR/RXR heterodimer
binds vitamin D response elements (VDREs) in DNA and recruits
co-regulatory protein complexes to modulate the expression of
hundreds of genes. In addition to acting as a ligand-activated
transcription factor, the VDR is also thought to activate cell sig-
naling pathways independent of its genomic effects [2].
The multiple steps in vitamin D bioactivation are controlled
by intricate regulatory pathways [1]. CYP27B1 expression in the
renal proximal tubule is stimulated by the parathyroid hormone
(PTH), which is regulated by free serum calcium levels.
1,25(OH)2D itself can directly and indirectly inhibit CYP27B1
expression, thereby providing a tight negative feedback loop.
CYP27B1 expression in keratinocytes is stimulated by both PTH
and inﬂammatory cytokines such as TNFa and IFNc.
1,25(OH)2D negatively regulates its own activity in these cells
by inducing the expression of the 1,25(OH)2D catabolic enzyme,
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Fig. 1. Vitamin D is obtained from dietary sources and through the photochemical conversion of 7-dehydrocholesterol in the skin. It binds to vitamin D-binding
protein and is transported to the liver, where it is hydroxylated by 25-hydroxylases to form 25(OH)D, a stable metabolite that is the best single indicator of vitamin D status.
A second hydroxylation step, mediated by the 1a-hydroxylase CYP27B1 in the kidneys and other extrarenal tissues, produces the most active metabolite 1,25(OH)2D, which
signals primarily through the VDR, resulting in pleiotropic physiological effects, as highlighted in the Fig. 1,25(OH)2D is catabolized by CPY24A1 to its inactive metabolite,
calcitroic acid.
JOURNAL OF HEPATOLOGYsynthesis of 1,25(OH)2D in macrophages are induced by both
inﬂammatory cytokines, such as IFNc, and toll-like receptor
(TLR) ligands, such as lipopolysaccharide. Because vitamin D
metabolism is controlled by multiple factors, the amount of vita-
min D consumed in the diet is only one of many variables that
determine the local activity of the vitamin D system. The levels
of vitamin D binding protein and VDR are additional variables
that strongly inﬂuence the magnitude of the biological effects
of vitamin D.
VDR activation by 1,25(OH)2D has long been known to
increase intestinal calcium and phosphate absorption, fostering
healthy bones. A growing number of recent studies reveal pleio-Journal of Hepatology 201tropic roles of 1,25(OH)2D beyond bone and calcium metabolism,
including the induction of antimicrobial genes and the reduction
of inﬂammation and ﬁbrogenesis [1]. Given the prevalence of
bone disease, inﬂammation, and ﬁbrosis in HCV-positive patients,
both classical and newly-discovered effects of vitamin D may be
relevant to disease management.Vitamin D deﬁciency in patients with liver disease
Knowledge of the widespread physiological importance of vita-
min D raises concern about the risks of vitamin D deﬁciency.3 vol. 58 j 184–189 185
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Focusing on bone, several groups have attempted to identify
markers that can be used to determine whether a patient’s vita-
min D status is optimal. A panel assembled by the Institute of
Medicine (IOM) determined that a serum 25(OH)D concentration
of 20 ng/ml is sufﬁcient for the majority of healthy adults, but
also determined that a concentration of 16 ng/ml is insufﬁcient
for about 50% of healthy adults, suggesting that there is very little
margin of error at a 25(OH)D level of 20 ng/ml [3]. A panel from
the Endocrine Society concluded that 32 ng/ml should be used as
the threshold of 25(OH)D sufﬁciency in patients with various dis-
ease conditions [4]. It is not clear whether the optimal level of
25(OH)D is the same for adults of all racial groups, which may
be an important issue when considering these guidelines.
While serum levels of 25(OH)D are the best single surrogate
marker of vitamin D status, PTH levels provide a second useful
marker, and skeletal homeostasis is inﬂuenced by the combined
effect of these two hormones. There is high inter-individual var-
iability in the relationship between 25(OH)D and PTH levels.
With serial testing, a patient’s vitamin D status can be optimized
by increasing vitamin D supplements until a 25(OH)D level is
reached that maximally suppresses PTH. This approach is time
consuming and costly, and the ﬁnancial burden of widespread
vitamin D testing is becoming recognized as an increasingly sig-
niﬁcant issue [5]. Some have advocated that screening efforts
should be focused on speciﬁc high risk individuals; however, a
recent study has shown that 25% of a group of young physicians
had 25(OH) D levels below 20 ng/ml, despite their lack of estab-
lished risk factors [6]. Whatever the cost-effectiveness of vitamin
D testing in the general public, the beneﬁts to HCV-positive
patients are likely to be greater because of their susceptibility
to bone disease and increased risk of bone fracture [7–11].
It is important to keep in mind that the estimates of the
25(OH)D levels needed for optimal health are based exclusively
on skeletal outcomes. The levels required for the non-classical
functions of vitamin D have yet to be established and are under
dispute [3,4,12]. The ﬁrst solid information about the level for a
non-skeletal outcome is likely to come from the infectious dis-
ease ﬁeld where intervention trials can be completed in a rela-
tively short period of time. Intriguingly, active tuberculosis
increases seasonally as 25(OH)D levels fall [13], suggesting that
optimal 25(OH)D levels could be determined for this disease by
conducting randomized trials of vitamin D supplements. Mean-
while, a growing body of evidence indicates that higher levels
of vitamin D and calcium may protect against colon cancer, and
possibly other cancers, including hepatocellular carcinoma; how-
ever, deﬁnitive trials have not been carried out [3,7].
A large number of studies have examined the relationship
between the vitamin D status of patients with chronic hepatitis
C and disease outcome [7,14,15]. The majority found that HCV-
positive patients have depressed 25(OH)D levels. A large study
conducted in Sicily found that mean serum 25(OH)D levels were
signiﬁcantly lower than in healthy, age, and sex-matched con-
trols (25.1 ± 9.9 ng/ml vs. 43.1 ± 10.2 ng/ml; p <0.0001), and that
73% of the HCV-positive patients had 25(OH)D levels below
30 ng/ml, in contrast to only 6% of the control subjects [16]. It
is possible that HCV depresses 25(OH)D levels by altering lipid
metabolism; a recent study has shown that HCV reduces produc-
tion of 7-dehydrocholesterol, the precursor of endogenously-pro-
duced vitamin D [17]. Most studies indicate that the severity of
vitamin D deﬁciency correlates with the severity of liver disease.
In addition to low 25(OH)D levels, a recent study of VDR genetic186 Journal of Hepatology 201polymorphisms has found that the bAt (CCA) haplotype is signif-
icantly associated with ﬁbrosis progression rate as compared to
the bat (CAA) and BaT (TAG) haplotypes [18]. While observational
studies cannot establish a causal link between low 25(OH)D lev-
els and liver disease progression, there are many ways in which
vitamin D deﬁciency might plausibly play a role in pathogenesis.Vitamin D as a down-modulator of inﬂammation
Chronic HCV infection is associated with intrahepatic inﬂamma-
tion and enhanced circulating levels of multiple inﬂammatory
cytokines including members of the TNF superfamily, a complex
group of ligands and receptors that are involved in cell survival,
death and differentiation. Circulating TNFa and soluble TNF recep-
tor (TNFR) levels are elevated in patientswith chronicHCV relative
to controls, and serumTNFR levels correlatewith the grade of liver
inﬂammation [19,20]. TNFa is strongly linked to insulin resistance,
and the elevated levels of this cytokine in HCV-positive patients
are thought to promote the development of type 2 diabetes, which
is associated with adverse outcomes [21].
Hepatic TNFa expression is highly correlated with hepatic
toll-like receptor (TLR)2 and TLR4 expression in HCV-infected
patients [22], and a similar correlation exists between serum lev-
els of TNFa and TLR2 expression on circulating monocytes [23].
Some data suggest that a proinﬂammatory cytokine milieu pro-
motes HCV replication; siRNA-based silencing of multiple mem-
bers of the proinﬂammatory NFjB signaling pathway inhibits
HCV RNA replication [24]. Further evidence of the importance
of TNFa in HCV infection is provided by a double-blinded ran-
domized, placebo controlled trial of 50 patients with chronic
HCV, in which treatment with etanercept, a TNFa antagonist,
improved the virologic response to IFN and ribavirin therapy [25].
Another proinﬂammatory factor that is strongly associated
with HCV infection is the chemokine CXCL10 (a.k.a., interferon
gamma-inducible protein 10), which exhibits strong chemotactic
effects on effector T cells. CXCL10 levels are elevated inHCV-positive
patients compared with healthy controls and correlate with viral
load, ALT elevations, and the extent of hepatic inﬂammation [26].
There is a highly statistically signiﬁcant association between
serum CXCL10 levels and the likelihood of treatment failure;
however, it is not known if the relationship is causal. A truncated
antagonistic form of CXCL10 was recently discovered [27], and
more information about this new form is needed to understand
the relationship between CXCL10 and treatment outcome.
If proinﬂammatory cytokines and chemokines promote HCV
persistence and disease progression, vitamin D’s anti-inﬂamma-
tory effects may be beneﬁcial. These effects are illustrated by
studies showing that treatment of human monocytes, macro-
phages and myeloid dendritic cells with 1,25(OH)2D downregu-
lates TLR expression, reduces the production of multiple
inﬂammatory factors, including TNFa and CXCL10, and promotes
a more tolerogenic phenotype [28–31]. Consistent with these
results, circulating 25(OH)D levels inversely correlate with mono-
cyte TLR expression and with seasonal differences in TLR-induced
TNFa production by peripheral blood mononuclear cells [32,33].
Due in part to these tolerogenic effects in antigen presenting cells,
vitamin D also inhibits inﬂammatory T cell responses, reducing
the production of IFNc and IL-17 in favor of IL-4 and IL-10 [34].
These ﬁndings suggest that vitamin D deﬁciency is likely to exac-
erbate chronic inﬂammation in HCV-positive patients.3 vol. 58 j 184–189
Key Points
• Vitamin D production and turnover are highly regulated
processes involving a complex array of feedback loops,
hormonal inputs, and signal transduction pathways.
The pleiotropic effects of vitamin D allow it to integrate
mineral homeostasis with inflammatory responses,
fibrogenesis, and microbial defenses
• The main circulating form of vitamin D is 
25-hydroxyvitamin D. This metabolite can be converted
to the active form, 1,25(OH)2D, by the enzyme 
CYP27B1. Local production of 1,25(OH)2D allows 
targeted paracrine/autocrine effects
• Many cohort studies show that the majority of patients
with hepatitis C virus (HCV) infection and other liver
diseases have levels of vitamin D that increase the risk
of bone disease. The severity of vitamin D deficiency
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Vitamin D as a downregulator of ﬁbrogenesis
Progressive liver ﬁbrosis is a dreaded consequence of HCV infec-
tion. Advanced ﬁbrosis/cirrhosis is associated with reduced viro-
logic response rates [35]. Several association studies demonstrate
that vitamin D levels inversely correlate with the liver ﬁbrosis
stage [7,14]. This could conceivably be related to the anti-
inﬂammatory effects of vitamin D, given the contribution of
inﬂammatory cell recruitment to hepatic ﬁbrosis progression. In
vitro studies establish that 1,25(OH)2D treatment also directly
inhibits the proliferation and pro-ﬁbrotic phenotype of hepatic
stellate cells and reduces thioacetamide-induced liver ﬁbrosis
in rats [36]. Vitamin D analogues have been found to similarly
reduce renal ﬁbrosis through multiple mechanisms in animal
models of obstructive nephropathy [37]. These ﬁndings suggest
that vitamin D deﬁciency may contribute to liver ﬁbrosis and that
vitamin D supplementation may have anti-ﬁbrotic effects in
HCV-positive patients.correlates with the severity of liver disease, and
advanced liver disease is associated with an increased
risk of bone fracture. Vitamin D supplements should be
prescribed at doses that maintain 25-hydroxyvitamin D
levels at, or above 20 ng/ml. Many patients will require
2000 to 4000 IU of nutritional vitamin D per day to 
achieve this target
• Several studies suggest that optimal vitamin D levels
may increase the likelihood of successful antiviral 
treatment in HCV-positive patients treated with interferon
and ribavirin, but the results are inconsistent and require
further confirmation. Polymorphisms in genes in the
vitamin D pathway, such as vitamin D binding protein,
vitamin D receptor, and enzymes involved in vitamin D
metabolism, should be considered when evaluating the
significance of vitamin D in interferon-based treatment
responseVitamin D and the response to antiviral treatment
The anti-inﬂammatory and anti-ﬁbrotic roles of vitamin D indi-
cate that vitamin D has the potential to reduce HCV-mediated
liver disease and, perhaps, to positively contribute to treatment
outcome. It is well established that vitamin D plays an important
antibacterial role by regulating cathelicidin expression in human
monocytes [38]. A number of studies now suggest that vitamin D
may also have analogous effects, as evidenced by the fact that
vitamin D and its metabolites can synergize with IFN treatment
to directly inhibit HCV RNA replication in vitro [39,40]. Consistent
with these ﬁndings, a growing body of clinical data supports a
positive role for vitamin D in the virological response to therapy.
Several association studies have examined 25(OH)D levels in
patients with chronic HCV and most, though not all, report a posi-
tive correlation between 25(OH)D levels and the likelihood of
achieving an SVR [7,14]. The VDR bAt (CCA) haplotype has also
been found to be negatively associated with a failure to respond
to therapy [41], as have polymorphisms in the vitamin D binding
protein gene [42]. In addition, a small number of studies have
reported the impact of vitamin D supplementation on treatment
outcome. A retrospective review of patients in Italy who were
treated with interferon and ribavirin for recurrent HCV post-
transplantation found that concurrent treatment with vitamin
D (for bone disease) resulted in signiﬁcantly higher SVR rates
[43]. In addition, two recent randomized clinical trials examined
the effect of vitamin D3 (2000 IU/day) in conjunction with con-
ventional interferon and ribavirin therapy and showed that vita-
min D supplementation signiﬁcantly enhanced the SVR rates of
treatment-naïve patients infected with HCV genotype 1 (86%
for the supplemented group vs. 42% for the controls, p <0.001)
and genotypes 2–3 (95% for the supplemented group vs. 77% of
the controls, p <0.001) [44,45].Conclusions
Vitamin D is increasingly becoming recognized as an important
physiological regulator with pleiotropic effects. A growing body
of experimental and clinical evidence suggests that vitamin D
deﬁciency is a risk factor in HCV-infected patients and thatJournal of Hepatology 201vitamin D supplementation might protect against liver disease
progression and improve responses to treatment. There is still a
lack of consensus on optimal 25(OH)D target levels and dosing
strategies. The existing evidence highlights the need for addi-
tional well-designed clinical trials to evaluate the effects of vita-
min D supplementation. The outcomes should include effects on
the ﬁbrosis progression rate (in patients with ongoing HCV repli-
cation and in patients who achieve a SVR), the incidence of hepa-
tocellular carcinoma, and the incidence of bone fractures. In light
of data showing protective effects of vitamin D supplementation
in preventing inﬂuenza virus infection [46], studies of vitamin D
supplementation in HCV patients should also examine vaccine
responses and susceptibility to infectious diseases. Given that
the relationships between vitamin D and chronic inﬂammation
and progressive hepatic ﬁbrosis are not unique to HCV infection,
and that vitamin D deﬁciency may also be a factor in other liver
diseases [7], clinical trials to study the effects of vitamin D sup-
plementation in HCV patients are likely to be broadly relevant
to the ﬁeld of hepatology. Although dose-response data are lim-
ited, many liver disease patients will likely require relatively high
doses of nutritional vitamin D to achieve 25(OH)D levels above
20 ng/ml. Until clinical data are available, 4000 IU/day is a3 vol. 58 j 184–189 187
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reasonable daily dose for patients with baseline 25(OH)D levels
below 10 ng/ml and 2000 IU/day is an appropriate starting dose
for patients with levels between 10 and 20 ng/ml.Conﬂict of interest
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or conﬂict of interest with respect to this manuscript.
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